Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis

Autoimmunity Reviews

Volumn 12, Issue 12, 2013, Pages 1123-1128

  Zhu, Qing ^a,b   Liu, Mei ^b,c   Dai, Liping ^b,d   Ying, Xia ^a   Ye, Hua ^b,d   Zhou, Yusen ^e   Han, Suxia ^a   Zhang, Jian Ying ^b,d  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d ZHENGZHOU UNIVERSITY   (China)

^e BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Autoantibody; Cancer; Immunodiagnosis; Immunoproteomics; Tumor associated antigen

Indexed keywords

ANNEXIN; AUTOANTIBODY; CANCER TESTIS ANTIGEN; CHAPERONIN 60; COMPLEMENTARY DNA; CYTOKERATIN 13; CYTOKERATIN 19; FK 506 BINDING PROTEIN; GLUCOSE REGULATED PROTEIN 78; GLUTATHIONE TRANSFERASE A1; GLYOXALASE; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN G; MANGANESE SUPEROXIDE DISMUTASE; MONOPHENOL MONOOXYGENASE; PEROXIREDOXIN 1; PROFILIN; PROTEIN P53; TROPOMYOSIN; TUMOR ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIGEN DETECTION; AUTOIMMUNE DISEASE; CANCER DIAGNOSIS; CANCER IMMUNOLOGY; CANCER PATIENT; CHRONIC HEPATITIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOASSAY; IMMUNOBLOTTING; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MASS SPECTROMETRY; PROTEOMICS; REVIEW; SERODIAGNOSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

AUTOANTIBODY; CANCER; IMMUNODIAGNOSIS; IMMUNOPROTEOMICS; TUMOR-ASSOCIATED ANTIGEN;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; NEOPLASMS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84884700982     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.06.015     Document Type: Review

References (46)

1. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet 1993, 9:138-141.
2. Sarasin A. An overview of the mechanisms of mutagenesis and carcinogenesis. Mutat Res 2003, 544:99-106.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
4. Tan E.M. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001, 108:1411-1415.
5. Looi K.S., Nakayasu E.S., Diaz R.A., Tan E.M., Almeida I.C., Zhang J.Y. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res 2008, 7:4004-4012.
6. Zhang J., Wang K., Zhang J., Liu S.S., Dai L., Zhang J.Y. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res 2011, 10:2863-2872.
7. Peng B., Huang X., Nakayasu E.S., Petersen J.R., Qiu S., Almeida I.C., et al. Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis. J Proteome Res Mar 15 2013, [in press, Epub ahead of print].
8. Tan E.M., Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008, 222:328-340.
9. Zhang J.Y., Tan E.M. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn 2010, 10:321-328.
10. Soussi T. p53 antibodies in the sera of patients with various types of cancer. A review. Cancer Res 2000, 60:1777-1788.
11. Crawford L.V., Pim D.C., Bulbrook R.D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30:403-408.
12. Looi K., Megliorino R., Shi F.D., Peng X.X., Chen Y., Zhang J.Y. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep 2006, 16(5):1105-1110.
13. Yamamoto A., Shimizu E., Takeuchi E., Houchi H., Doi H., Bando H., et al. Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology 1999, 56:129-133.
14. Disis M.L., Pupa S.M., Gralow J.R., Dittadi R., Menard S., Cheever M.A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997, 15:3363-3367.
15. Junttila M.R., Puustinen P., Niemela M., Ahola R., Arnold H., Bottzauw T., et al. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130(1):51-62.
16. Soo Hoo L., Zhang J.Y., Chan E.K.L. Cloning and characterization of a novel 90kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002, 21:5006-5015.
17. Liu W., Peng B., Lu Y., Xu W., Qian W., Zhang J.Y. Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev 2011, 10(6):331-335.
18. Keene J.D. Why is Hu where? Shuttling of early response gene messenger RNA subsets. Proc Natl Acad Sci U S A 1999, 96:5-7.
19. Stockert E., Jager E., Chen Y.T., Scanlan M.J., Gout I., Karbach J., et al. A survey of humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998, 187:1349-1354.
20. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-992.
21. Daniels T., Zhang J., Gutierrez I., Elliot M.L., Yamada B., Heeb M.J., et al. Antinuclear autoantibodies in PCa: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 2005, 62:14-26.
22. Winter S.F., Minna J.D., Johnson B.E., Takahashi T., Gazdar A.F., Carbone D.P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992, 52:4168-4174.
23. Lu M., Nakamura R.M., Dent E.D., Zhang J.Y., Nielsen F.C., Christiansen J., et al. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol 2001, 159:945-953.
24. Anderson K.S., LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005, 4:1123-1133.
25. Old L.J., Chen Y.T. New paths in human cancer serology. J Exp Med 1998, 187:1163-1167.
26. Zhang J.Y., Casiano C.A., Peng X.X., Koziol J.A., Chan E.K.L., Tan E.M. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003, 12:136-143.
27. Imai H., Chan E.K.L., Kiyosawa K., Fu X.D., Tan E.M. Novel nuclear antoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest 1993, 92:2419-2426.
28. Landberg G., Tan E.M. Characterization of a DNA-binding nuclear autoantigen mainly associated with S phase and G2 cells. Exp Cell Res 1994, 212:255-261.
29. Casiano C.A., Landberg G., Ochs R., Tan E.M. Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis. J Cell Sci 1993, 106:1045-1056.
30. Zhang J.Y., Chan E.K.L., Peng X.X., Tan E.M. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 1999, 189:1101-1110.
31. Chen Y.T., Scanlan M.J., Sahin U., Türeci Ö., Gure A.O., Tsang S. A testicular antigen aberrantly expressed in human cancers detected by autologous antibodyscreening. Proc Natl Acad Sci U S A 1997, 94(5):1914-1918.
32. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995, 92:11810-11813.
33. Chambers J.C., Keene J.D. Isolation and analysis of cDNA clones expressing human lupus La antigen. Proc Natl Acad Sci U S A 1985, 82:2115-2119.
34. Le Naour F., Brichory F., Beretta L., Hanash S.M. Identification of tumor-associated antigens using proteomics. Technol Cancer Res Treat 2002, 1:257-262.
35. Le Naour F., Brichory F., Misek D.E., Brechot C., Hanash S.M., Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 2002, 1:197-203.
36. Ginestier C., Charafe-Jauffret E., Bertucci F., Eisinger F., Geneix J., Bechlian D., et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 2002, 161:1223-1233.
37. Tyers M., Mann M. From genomics to proteomics. Nature 2003, 422:193-197.
38. Gygi S.P., Corthals G.L., Zhang Y., Rochon Y., Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 2000, 97:9390-9395.
39. Iwadate Y. Clinical proteomics in cancer research-promises and limitations of current two-dimensional gel electrophoresis. Curr Med Chem 2008, 15:2393-2400.
40. Imai H., Nakano Y., Kiyosawa K., Tan E.M. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 1993, 71:26-35.
41. Imai H., Kiyosawa K., Chan E.K.L., Tan E.M. Autoantibodies in viral hepatitis related hepatocellular carcinoma. Intervirology 1993, 35:73-85.
42. Zhang J.Y., Zhu W., Imai H., Kiyosawa K., Chan E.K.L., Tan E.M. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol 2001, 125:3-9.
43. Koziol J.A., Zhang J.Y., Casiano C.A., Peng X.X., Shi F.D., Feng A.C., et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003, 9:5120-5126.
44. Shi F.D., Zhang J.Y., Liu D., Rearden A., Elliot M., Nachtsheim D., et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 2005, 63:252-258.
45. Zhang J.Y., Megliorino R., Peng X.X., Tan E.M., Chen Y., Chan E.K.L. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 2007, 46:107-114.
46. Chen Y., Zhou Y., Qiu S., Wang K., Liu S., Peng X.X., et al. Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett 2010, 289:32-39.